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Beta cell failure is a central feature of type 2 diabetes (T2D), but the molecular
underpinnings of the process remain only partly understood. It has been suggested
that beta cell failure in T2D involves massive cell death. Other studies ascribe beta
cell failure to cell exhaustion, due to chronic oxidative or endoplasmic reticulum stress
leading to cellular dysfunction. More recently it was proposed that beta cells in T2D may
lose their differentiated identity, possibly even gaining features of other islet cell types.
The loss of beta cell identity appears to be driven by glucotoxicity inhibiting the activity
of key beta cell transcription factors including Pdx1, Nkx6.1, MafA and Pax6, thereby
silencing beta cell genes and derepressing alternative islet cell genes. The loss of beta
cell identity is at least partly reversible upon normalization of glycemia, with implications
for the reversibility of T2D, although it is not known if beta cell failure reaches eventually
a point of no return. In this review we discuss current evidence for metabolism-driven
compromised beta cell identity, key knowledge gaps and opportunities for utility in the
treatment of T2D.
Keywords: Pax6, dedifferentiation, reprogramming, beta cell failure, type 2 diabetes mellitus, ghrelin, gastrin,
oxidative stress
INTRODUCTION
The pathogenesis of T2D is thought to begin with lifestyle-induced insulin resistance, which
gradually increases the demand on beta cells to secrete insulin. In the majority of people with
this condition, increased beta cell function successfully maintains normoglycemia. In about 20%
of insulin resistant individuals, beta cells eventually fail to deliver a sufficient amount of insulin,
resulting in the development of glucose intolerance and ultimately fasting hyperglycemia and overt
diabetes (Mokdad et al., 2001; Narayan et al., 2007; Alejandro et al., 2015). The genetic, cellular,
and molecular basis for this failure of beta-cell compensation for increased demand has been
studied intensively, but remains incompletely understood. Multiple theories have been proposed,
ranging from low post natal beta-cell mass due to genetic or environmental (intrauterine) factors,
to beta-cell factors resulting in differential susceptibility to metabolic stressors such as chronic
hyperglycemia. The possible mechanisms leading to beta-cell failure can be broadly divided into
three, not mutually exclusive categories as follows (summarized in Figure 1).
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CATEGORIES OF BETA CELL FAILURE
Reduced Beta Cell Numbers
Histological analysis of beta cell mass in autopsies of people
with T2D has revealed that T2D patients have up to 50%
decrease in beta cell mass compared with healthy individuals
of the same BMI (Clark et al., 1988; Butler et al., 2003; Yoon
et al., 2003; Rahier et al., 2008). This observation, combined
with a qualitative histological demonstration of beta cell death,
raised the possibility that beta cell failure involves beta cell
death, resulting in reduced beta cell mass that cannot deliver
sufficient insulin (Butler et al., 2003). Alternatively, it is possible
that individuals with a lower potential for beta cell regeneration
fail to increase beta cell mass when demand is higher, opening
a gap between demand and supply that eventually causes
hyperglycemia. It is also possible that individuals with genetically
or environmentally determined low beta cell mass are prone to
T2D, due to a compromised capacity for beta cell compensation
upon increased demand later in life (Van Assche et al., 1977;
Garofano et al., 1997; Petrik et al., 1999; Meier, 2009). The latter
idea is consistent with a large variation in beta cell mass among
healthy individuals, as observed in autopsies (Meier et al., 2008).
In the absence of tools to assess the dynamics of beta cell mass
in a given individual over time, it remains difficult to distinguish
between these possibilities. However a common feature is that
beta cell failure results, at least in part, from an irreversible
deficiency in beta cell numbers. We note though that the modest
reduction in beta cell mass is unlikely the “whole story,” since
surgical removal of 50% of the functional beta-cell mass is not
associated with glucose intolerance, at least not in the short-term
(Kendall et al., 1990; Seaquist et al., 1996; Robertson et al., 2002).
Beta Cell Dysfunction
A chronic load on beta cells may lead to severe dysfunction, such
that histologically normal beta cells fail to secrete insulin properly
in response to glucose. It has been proposed that metabolic
load may lead to severe endoplasmic reticulum (ER) stress in
beta cells, and that cellular adaptation to ER stress- namely the
unfolded protein response (UPR)- can reduce glucose-stimulated
insulin secretion (Izumi et al., 2003;Back and Kaufman, 2012;
Evans-Molina et al., 2013). Alternatively, chronic oxidative stress
resulting from improper glucose metabolism may cause beta
cell dysfunction (Kaneto et al., 1999, 2002; Krauss et al., 2003;
Robertson et al., 2003, 2007; Poitout and Robertson, 2008). Beta
cells appear to be particularly sensitive to oxidative stress, as
they express low levels of genes responsible for inactivation
of reactive oxygen species (ROS). ROS are normally produced
through mitochondrial metabolism, which is central in glucose-
stimulated insulin secretion, and in normal conditions play a
role in signaling pathways in beta cells. It was proposed that
excessive ROS, generated as a consequence of persistent high
glucose metabolism, suppress beta cell mitochondrial activity
and other components of the insulin secretion pathway, thus
leading to beta cell dysfunction (Lenzen, 2008; Drews et al., 2010).
A characteristic of chronic beta cell stress is a situation termed
“beta cell exhaustion,” where seemingly normal beta cells (judged
by histological analysis, potentially including immunostaining
for beta cell markers or even expression analysis) fail to
secrete insulin properly. Per our current understanding of
the phenomenon, beta cell exhaustion should be perfectly
reversible upon normalization of glycemia. Indeed, short term
(2–3 weeks) of intensive insulin treatment results in improved
beta-cell function in patients with new-onset or long-standing
T2D (Turner et al., 1976; Garvey et al., 1985; Glaser et al.,
1988; Ilkova et al., 1997; Li et al., 2004; Ryan et al., 2004).
The mechanism of improved beta-cell function is not fully
understood, although improved proinsulin processing has been
suggested (Glaser et al., 1988). That being said, although the
positive effect on beta-cell function may be clinically significant,
it is partial and in many cases transient, suggesting that reversible,
functional exhaustion per se does not entirely explain beta-cell
dysfunction seen in T2D. Other attempts in this context involve
forcing “beta cell rest,” for example via temporary pharmacologic
prevention of membrane depolarization, calcium entry, and
insulin secretion (Greenwood et al., 1976; Guldstrand et al., 2002;
Yoshikawa et al., 2004). Despite some positive initial reports,
such approaches have not yielded a consistent improvement of
beta cell function, potentially because of the interference with key
signaling pathways within the beta cells. Furthermore, inhibition
of beta-cell membrane depolarization may prevent the normal
compensatory response to increased glycemic load (Porat et al.,
2011).
Loss of Beta Cell Identity
The beta-cell can be defined on a purely functional level as a cell
capable of synthesizing, processing and secreting mature insulin
in response to metabolic, hormonal and neurologic stimuli, or
on a molecular level as a cell that expresses the full complement
of genes associated with normal, regulated insulin secretion.
In this review, we use the former definition to define “beta-
cell function/dysfunction” as discussed above, and the latter
definition to define “beta-cell identity.” Thus, for the purpose of
this review, we define the loss of beta-cell identity as the failure
to express the full complement of beta-cell genes or expression of
genes not normally expressed in a mature healthy beta-cell.
Recently, a landmark study from the Accili group has
described a mechanism for profound loss of beta cell function
in diabetes, not involving cell death. Based on studies in mice
with Foxo1-deficient beta cells they suggested that high metabolic
load may perturb beta cell identity, via a process involving loss
of the beta cell gene expression program, reversal to a fetal state
(dedifferentiation), and reprogramming to express hormones of
other islet cell types including glucagon and somatostatin (Talchai
et al., 2012). Indeed, in mouse models of T2D, Talchai et al. (2012)
found that the endocrine cell mass is maintained, revealed by
immunostaining of chromogranin A and synaptophysin, despite
massive loss of insulin, Pdx1 and MafA (termed “empty beta
cells”). Recent studies have lent support to this reprograming
model, including evidence for loss of beta cell identity in human
T2D, although the extent of the phenomenon and its relevance
for pathology remain unclear (Guo et al., 2013; White et al.,
2013; Spijker et al., 2015; Brereton et al., 2016; Cinti et al., 2016).
These studies have also shown that the phenomenon is largely
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FIGURE 1 | Models for beta cell failure in T2D. The illustration shows the architecture and endocrine cell composition of a normal pancreatic islet of Langerhans
(top) and potential changes, distinguished by beta cell fate, that lead to beta cell failure in T2D (bottom). Different colors indicate different islet cell type. ε, ghrelin; G,
gastrin, E, endocrine cell with empty granules (no hormone is produced).
reversible, such that dedifferentiated/reprogrammed beta cells
appear to revert to their original identity when exposed to normal
glucose levels (Laybutt et al., 2007; Blum et al., 2014; Brereton
et al., 2014; Wang et al., 2014). It remains unclear whether the
loss or change of beta cell phenotype becomes irreversible at
some point. The latter is a crucial point, with implications to the
feasibility of restoring beta cell mass in patients with T2D.
Recent work by our own group has contributed the
observation that beta cells in human and rodent T2D may turn
on expression of gastrin, a hormone typically expressed in the
pancreas only during embryonic development and in rare islet
cell tumors (Suissa et al., 2013; Dahan et al., 2017). While the
physiological significance of gastrin expression remains unclear,
we were able to use it as a biomarker of compromised identity and
obtain insights into the dynamics and determinants of the process
(see below). Gastrin expression is induced in beta cells upon
exposure to high levels of glucose; importantly, gastrin expression
does not involve the fetal endocrine progenitor marker and
determinant neurogenin-3 (NeuroG3), which was proposed to
mediate beta cell dedifferentiation (Talchai et al., 2012; Brereton
et al., 2014; Wang et al., 2014). NeuroG3 mRNA and protein were
not detected in islets of diabetic db/db mice that express gastrin,
and gastrin expression in beta cells of diabetic mice occurred
even when the NeuroG3 gene was deleted. We also showed that
gastrin expression is reversible upon normalization of glycemia.
Interestingly, while gastrin expression in diabetic mice occurred
almost entirely in beta cells, islets of humans with T2D had
gastrin expression in both beta and delta cells, with the latter
accounting for most T2D-related islet gastrin expression. These
findings suggest that metabolic stress causes the expression of
gastrin in beta cells without going through a fetal-like stage.
Therefore, the term “dedifferentiation” might be inappropriate,
and the phenomenon is better described as reversible loss, partial
or complete, of beta cell identity. Figure 2 shows a visual example
of islets in diabetic mice and humans that express gastrin.
MOLECULAR MECHANISMS LINKING
METABOLIC STRESS TO LOSS OF BETA
CELL IDENTITY
Emerging evidence from multiple lines of research is suggesting
how metabolic stress, in particular hyperglycemia, may lead to a
compromised cellular identity of beta cells.
Role of Transcription Factors
As might have been expected, metabolic stress appears to
converge on perturbation of the activity of transcription factors,
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FIGURE 2 | Gastrin expression in islets of mice and humans with type
2 diabetes. Gastrin expression in the pancreas is normally limited to fetal life.
Islets of healthy adult mice and humans normally do not express gastrin.
Strikingly, gastrin-positive cells re-appear in islets of mice and humans with
type 2 diabetes. In diabetic db/db mice, gastrin is induced in beta cells; in
humans with T2D, gastrin is induced mostly in delta cells. Sections are
immunostained for gastrin (red), insulin (green), and Pdx1 or Dapi (blue). White
arrows point to the gastrin positive cells. Micrographs are from our recently
published paper (Dahan et al., 2017).
the central regulators of cell identity and fate. We have extensive
knowledge on the roles of many transcription factors in beta cell
development, based on gene deletion experiments (reviewed in
Mastracci and Sussel, 2012). However, most of these studies have
disrupted the gene of interest starting in early developmental
stages, using Insulin-Cre mice that delete the gene as early
as insulin expression starts. Consequently, it is difficult to
distinguish between a requirement for a particular gene in beta
cell differentiation/maturation, and a role in the maintenance of
mature beta cell function and identity. More recently, a number
of studies used the more precise control over gene deletion
afforded by Insulin-CreER mice, to induce gene deletion in
adult beta cells using tamoxifen injection to activate Cre. These
studies have revealed a requirement for multiple transcription
factors in adult beta cells, and have established a paradigm
where the maintenance of adult beta cell identity requires the
continuous activity of many transcription factors. For example,
deletion of Pdx1 in adult beta cells leads to loss of beta cell-
specific genes, and to the induction of alpha cell genes, most
prominently glucagon (Gao et al., 2014). Thus continuous activity
of Pdx1 in adult beta cells is required not only for expression
of beta cell genes but also for the prevention of expression of
alpha cell genes. Interestingly, glucagon expression following
Pdx1 deletion in beta cells is not stable; after 30 days, the
proportion of these glucagon-expressing cells decreased from
35% to less than 15%. This indicates that loss of Pdx1 leads to
a metastable state, which eventually shifts to other, more stable
and yet to be defined states. An additional example is Nkx6.1,
previously known to be important for beta cell differentiation
during embryonic development (Sander et al., 2000). Deletion
of Nkx6.1 in adult beta cells led to loss of beta cell-specific
genes and functions, and over time caused the appearance of
delta cell features including somatostatin expression (Taylor et al.,
2013). MafA was also shown to be important for maintaining
the transcriptional program of adult beta cells, and to prevent
expression of disallowed genes (Nishimura et al., 2015).
Recently, we have shown that Pax6, another transcription
factor previously implicated in developmental decisions, is
essential for the maintenance of beta cell identity (Swisa et al.,
2017). Deletion of Pax6 in adult beta cells led to a gradual loss
of insulin expression, and to the induction of multiple genes
characteristic of other islet cell types, including glucagon and
somatostatin, and most prominently the fetal hormone ghrelin
(Figure 3). Similarly, Nkx2.2 was found to be essential for the
maintenance of adult beta cell identity, as its deletion led to
down-regulation of beta cell genes and to the induction of genes
typical of alternative islet cell types (Gutierrez et al., 2017).
The main hormone induced in Nkx2.2-deficient beta cells was
somatostatin, similarly to the phenotype of Nkx6.1-deficient
beta cells (Schaffer et al., 2013). This may relate to Nkx2.2
being a transcriptional activator of Nkx6.1 (Sussel et al., 1998;
Watada et al., 2000). Finally, the transcriptional co-activator
LIM-Domain-Binding 1 (Ldb1), which is expressed preferentially
in adult islets, and its binding partner Isl1, are essential for
maintaining the expression of beta cell-specific genes by ensuring
proper enhancer-promoter looping in the beta cell genome
(Ediger et al., 2017).
Importantly for the concept of metabolic regulation of beta
cell identity, many of the transcription factors mentioned above,
specifically Pdx1, Nkx6.1, MafA and Pax6, as well as Foxo1,
are inactivated by hyperglycemia (Jonas et al., 1999; Talchai
et al., 2012; Guo et al., 2013; Brereton et al., 2014; Wang et al.,
2014; Cinti et al., 2016), providing a plausible mechanism for
compromised beta cell identity in diabetes. Notably, the factors
appear to respond to chronic, rather than acute, high glucose
levels; this suggests that their loss may not be the primary driver
of beta cell failure, but rather a contributor to a vicious cycle of
glucotoxicity.
Direct Repression of Alternative Islet Cell
Genes
How do transcription factors maintain beta cell identity? The
obvious mechanism is via direct transcriptional activation of beta
cell genes. This would explain reduced expression of beta cell
genes following deletion of such transcription factors. However,
the induction of non-beta cell genes following deletion of beta
cell transcription factors is more difficult to explain. Interestingly,
some well-established activators of beta cell genes have recently
been found to act also as direct repressors of non-beta cell genes.
This understanding is based on the integration of CHIP-Seq data
on binding sites of transcription factors, together with data on
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FIGURE 3 | Ghrelin expression following Pax6 loss in adult beta cells. Top, pancreatic islets with ghrelin expression following Pax6 deletion in adult beta cells.
Bottom left, deletion of pax6 was combined with Cre-mediated permanent expression of a yellow fluorescent protein (YFP) reporter. Bottom right, ghrelin-expressing
cells do not express insulin, yet expression of YFP proves that these were insulin+ beta cells prior to the deletion of Pax6. Micrographs were adjusted from our
published paper (Swisa et al., 2017).
genes up-regulated following transcription factor deletion. This
integration exposes genes that are considered direct repression
targets for a transcription factor. For example, Pdx1 binds and
represses MafB transcription, helping to prevent an alpha cell
program in beta cells (Gao et al., 2014). Rfx6, mostly known
as an activator of beta cell maturation and function genes, is
also a direct repressor of some “disallowed” beta cell genes
such as LdhA (Pullen et al., 2010; Piccand et al., 2014). Nkx6.1
was also found to directly bind and repress a large group of
genes, including the transcription factors Mnx1 and Rfx6 and
the hormone somatostatin (Taylor et al., 2013). While studying
how Pax6 controls beta cell identity, we discovered that it acts
primarily as a direct repressor of gene expression in beta cells
(Swisa et al., 2017). Hence in the absence (or inactivity) of
Pax6, the transcription of beta cell specific genes is reduced,
while the transcription of non-beta cell genes, such as alternative
hormone genes, is derepressed. These studies collectively suggest
that direct repression of non-beta cell genes is a central function
of many beta cell transcription factors. A particularly important
observation is that the regulatory effects of some beta cell
transcription factors changes from the developmental stages
to adults. For example, Nkx6.1 is necessary to repress Arx
expression in Ngn+ embryonic endocrine progenitors, but it
does not regulate Arx in differentiated beta cells (Schaffer et al.,
2013). Interestingly, Nkx6.1 is still bound to Arx promoter
in adult beta cells (Taylor et al., 2013) but does not execute
any regulatory effect. How exactly do beta cell transcription
factors act simultaneously as activators and repressors in the
same cell, is an important open question. Figure 4 presents
a simplified model for the transcriptional regulation of beta
cell identity, based on integration of our work with Pax6
deficient beta cells and studies of other transcription factors. We
propose that Pax6 normally binds and activates genes of beta
cell transcription factors and in addition, interacts with these
factors to activate other beta cell genes or to repress non-beta
cell genes. The transcriptional output (activation or repression)
will depend on the factors participating in the transcriptional
complex. Further investigation of the physical interactions and
transcriptional hierarchy between Pax6 and more beta cell
transcription factors (Arda et al., 2013) may shed light on
transcriptional control mechanisms in beta cells and their link to
metabolism.
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FIGURE 4 | Transcriptional activation and repression in the regulation of beta cell identity. A model presenting the dual role of beta cell transcription factors
as direct activators of beta cell genes and repressors of alternative islet cell genes. Pax6 activates the expression of key beta cell transcription factors such as
Nkx6.1, Pdx1, and MafA and also interacts with these factors at the protein level, to execute the specific transcriptional outcome, activation or repression. We
propose that the chromatin state and the other factors interacting in the transcriptional complex will determine the transcriptional activity.
Signaling from Metabolic Stress to Loss
of Transcription Factor Activity
What are the molecular mechanisms responsible for metabolic
inactivation of key beta cell transcription factors? An elegant
study from the Stein group (Guo et al., 2013) has shown
that oxidative stress inhibits the activity of Pdx1, Nkx6.1, and
MafA. Oxidative stress (mimicked in vitro by the addition of
hydrogen peroxide) appears to inactivate these factors via at least
two mechanisms: their activity as transcriptional activators is
reduced, and in addition they are translocated from the nucleus
to the cytoplasm where they are rapidly degraded. While the exact
nature of the effect of oxidative stress on these factors remains to
be elucidated, these findings provide a framework to understand
how metabolic stress, manifested as increased oxidative stress and
ROS, may impact gene expression in beta cells, including sensitive
nodes controlling cell identity.
In our own work with Pax6, a different mechanism appears
to be acting, as we have observed a significant down regulation
of Pax6 at the mRNA level in beta cells of hyperglycemic mice
(Swisa et al., 2017). The molecular mechanisms responsible for
downregulation of Pax6 transcription in diabetes remain to be
elucidated. We also note that in this case, relevance to the
situation in human diabetes is not yet proven; we have observed
downregualtion of Pax6 in diabetic db/db mice but not in islets
from humans with T2D.
Involvement of Membrane
Depolarization and Calcium Signaling in
Loss of Beta Cell Identity
Using gastrin expression as a biomarker for compromised beta
cell identity, we explored how high levels of glucose signal
to gastrin expression (Dahan et al., 2017). Surprisingly, we
found that components of the classic triggering pathway for
insulin secretion participate in the process. In the triggering
pathway, ATP generated by oxidative metabolism causes the
closure of ATP-dependent potassium channels (KATP channels);
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FIGURE 5 | Hyperglycemia-induced loss of beta cell identity. A model summarizing downstream components of glucose signaling required for beta cell
expression of gastrin following hyperglycemia. Red arrows, induction of beta cell reprograming; Yellow arrows, prevention of beta cell reprograming demonstrated by
genetic or pharmacological interventions.
the resulting depolarization of the beta cell membrane leads to
calcium entry, and the release of insulin granules. By preventing
the closure of KATP channel, pharmacologically (using diazoxide)
or genetically (using transgenic mice expressing a mutant
version of the KATP channel Kir6.2), we showed that glucose-
induced gastrin expression requires membrane depolarization.
Furthermore, we found that the calcineurin inhibitor tacrolimus
prevents glucose-induced gastrin expression; however, forced
membrane depolarization or forced calcium entry under
low glucose levels did not trigger gastrin expression. The
conclusion from these experiments was that hyperglycemia
triggers gastrin expression in beta cells via a pathway that includes
mitochondrial metabolism, membrane depolarization, calcium
entry and calcineurin activity; while membrane depolarization
and calcium entry are necessary for gastrin expression, they
are not sufficient. We speculate that the loss of beta cell
identity requires also the direct action of ROS derived
from aberrant mitochondrial metabolism, consistent with
the Stein model emphasizing the importance of oxidative
stress.
We note however that other studies, which have used
different biomarkers of compromised beta cell identity (e.g.,
the appearance of cells co-expressing insulin and glucagon)
in a model of KATP-channel mutant mice, concluded that
glucose triggers loss of beta cell identity regardless of membrane
depolarization (Brereton et al., 2014; Wang et al., 2014). It is
possible that different “illegitimate” programs of gene expression
in beta cells require different combinations of signaling events.
Figure 5 shows a graphic summary of signaling pathways shown
to mediate the effects of hyperglycemia on loss of beta cell
identity.
FRAGILE IDENTITY OF BETA CELLS vs.
ISLET CELL PLASTICITY
The evidence presented above concerns conditions of metabolic
stress, which compromise the identity of beta cells. Interestingly,
independent lines of research indicate that islet cell identity can
also be changed in the other direction, that is to drive non-
beta cells to express beta cell genes. This was most strikingly
demonstrated in studies from the Herrera group, which used
adult mice in which the vast majority of beta cells were
ablated using diphtheria toxin. This resulted in lethal diabetes,
which required insulin treatment. Strikingly, it was found
that a proportion of alpha cells in these mice underwent a
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FIGURE 6 | Intra-islet cell identity transitions. Summary of genetic manipulations that were shown to lead to intra-islet cell identity transitions in adult mice,
indicating high plasticity within the pancreatic endocrine lineage. Note the fetal or abnormal islet cell types, ε, ghrelin; G, gastrin; P, polyhormonal; E, endocrine with
empty granule. In most of the examples, only dominant transitions are presented. References cited in this figure: (1) Al-Hasani et al., 2013; (2) Brereton et al., 2014;
(3) Chera et al., 2014; (4) Courtney et al., 2013; (5) Dahan et al., 2017; (6) Gao et al., 2014; (7) Gutierrez et al., 2017; (8) Swisa et al., 2017; (9) Talchai et al., 2012;
(10) Thorel et al., 2010; (11) Taylor et al., 2013; (12) Wang et al., 2014.
conversion of identity to become insulin-producing beta cells
(Thorel et al., 2010). When beta cells where ablated in young
mice, a similar phenomenon of beta cell regeneration was
observed, but this time the origins were somatostatin-expressing
delta cells (Chera et al., 2014). Alpha cell reprogramming
to beta cells in adult mice appeared not to require cell
proliferation and to be NeuroG3-independent. In contrast, delta
cell reprogramming to beta cells in newborn mice was found to
involve dedifferentiation, expression of NeuroG3, proliferation
and differentiation. Additional studies from the Collombat group
found that genetic manipulations of the transcription factors
Pax4 and Arx in adult alpha cells can also drive their conversion
into functional insulin producing cells. Ectopic expression of
Pax4, which is essential for beta cell differentiation from
endocrine progenitors (Sosa-Pineda et al., 1997), was found to
trigger insulin expression in alpha cells (Al-Hasani et al., 2013). It
was suggested that Arx downregulation triggers this conversion
as Arx deletion in alpha cells was sufficient to mediate alpha to
beta cell reprograming, independently of Pax4 (Courtney et al.,
2013). Strikingly, induced GABA signaling in alpha cells was
recently shown to repress Arx and upregulate Pax4 in mouse
and human alpha cells, leading to their reprograming to beta
cells (Ben-Othman et al., 2017; Li et al., 2017), suggesting a
pharmacological path to acquisition of beta cell identity.
When combined with evidence for loss of beta cell identity
in diabetes, a picture emerges of a rather fragile identity of islet
cells, where metabolic insults compromise cell identity. A striking
common feature to all these models is the retention of islet cell
identity: stressed beta cells in diabetes may lose beta cell markers
and gain markers of alpha, delta, ghrelin or gastrin cells, but they
never convert to non-islet cells such as hepatocytes, for example.
Similarly, the formation of beta cells from non-beta cells appears
to occur mostly, if not solely, from other islet cells and not from
more distant lineages. Figure 6 summarizes current evidence of
bidirectional islet cell identity flow, from and to beta cells.
Thus, islet endocrine identity appears to be robust while islet
cell type identity is fragile and dependent on metabolic state.
What might be the molecular basis for this peculiar situation?
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A clue comes from comparisons of the transcriptome and
epigenome of distinct islet cell types, obtained recently from
FACS-sorted beta and alpha cells (Bramswig et al., 2013; Wang
et al., 2016). These studies have revealed that different islet cell
types are extremely similar both in their expression profile and
epigenetic makeup (patterns of histone modifications and DNA
methylome). The deep epigenetic similarity between different
islet cell types may explain intra-islet cell plasticity, from and to
beta cells, and the difficulty in generating islet cells from non-islet
tissue.
SUMMARY AND PERSPECTIVE
Compromised beta cell identity is emerging as an important
contributor to beta cell failure in diabetes. Most evidence so
far suggests that the phenomenon results from hyperglycemia-
induced inactivation of key transcription factors, acting as
activators of gene expression in beta cells as well as repressors
of non non-beta cell genes. Beta cells with a compromised
identity become dysfunctional and fail to secrete insulin in
response to glucose. They may show just loss of beta cell
genes, but also a gain of non-beta cell genes. Importantly, a
generic endocrine identity remains in such cells (e.g., they do
not reprogram to cells of the exocrine pancreas or other non-
islet cell types), and sometimes they even acquire expression
of genes typical to other islet cell types. The loss of beta cell
identity seen in diabetes, and even the acquisition of non-
beta cell identity, appear to be reversible upon normalization
of metabolism. Islet cell plasticity, while contributing to beta
cell failure in diabetes, may also work in the opposite direction
and be utilized to generate new beta cells from other islet
cell types. The concept of metabolic compromise of beta cell
identity opens up many fascinating questions, with implications
for our understanding of tissue dynamics and for approaches to
prevent and cure diabetes. Some key open questions in this field
include:
• Reversibility of changes. The loss of beta cell identity and the
acquisition of features of non-beta cell genes appear to be
reversible upon normalization of glucose levels. It remains
unclear whether at some point the acquisition of alternate islet
cell identity becomes stable, and independent of metabolic
state. This is important for loss of beta cell identity under stress,
but also for reprogramming of other cell types to beta cells.
• The involvement of NeuroG3 and fetal islet programs in
changes of islet cell identity. Several papers reported expression
of NeuroG3 in adult beta cells upon loss of key beta cell
transcription factors (Talchai et al., 2012; Taylor et al., 2013),
as well as in delta cells when they convert to beta cells after
extreme beta cell ablation (Chera et al., 2014). However it
remains unclear if NeuroG3 is required for these changes of
fate. At least the expression of gastrin in beta cells is NeuroG3-
independent (Dahan et al., 2017).
• The direction of identity changes. Metabolic insults were
reported to result in beta cell neogenesis, and at the same time
loss of beta cell identity. It will be essential to understand the
determinants of cell fate transitions within islets.
• The relative importance of compromised beta cell identity to beta
cell failure in diabetes, compared with beta cell death and beta
cell dysfunction.
Answers to these questions, which will surely emerge in
coming years, may suggest novel directions to prevent or reverse
beta cell failure in diabetes.
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